IW Capital led the Series A round to support team growth and international scaling.
"We’re pleased to be investing in Plumm as the company continues to grow in the UK and internationally. At IW Capital, we focus on backing businesses that are doing important work in growing markets, and it was clear that Plumm is well poised to expand their offering, having built a great platform to serve the underserved and expanding mental health market. We are thrilled to be working with Plumm on the next stage of their growth journey."
Northern Gritstone backed the Hull-based bioplastics developer to support team expansion and commercialisation.
"Everyday oil-based plastics are contributing to the global environmental crisis. Our vision is to offer brands an alternative product and through this transform the global plastics market. We are delighted to partner with Northern Gritstone. Their support, experience and investment will enable us to develop our team and deliver our commercial strategy."
The financing round was led by Sofinnova Partners, F-Prime Capital, Digitalis Ventures and Cambridge Innovation Capital.
"We’re delighted to have raised this Series A with such high-quality investors whose amazing networks and shared vision will help us deliver highly differentiated TCR cancer therapies. TCR therapeutics are very much at the dawn of their potential. We intend to replicate the success of therapeutic antibodies but build on this in a new dimension, by using the targeting domains of TCR receptors to take advantage of their much greater specificity for cancer cells compared to normal cells. The same logic can be used to target immunosuppressive biologics to tissues impacted by autoimmune disorders."
